Trade

with

Seattle Genetics Inc
(NASDAQ: SGEN)
AdChoices
34.65
-0.08
-0.23%
After Hours :
34.65
+0.00
+0.01%

Open

35.06

Previous Close

34.73

Volume (Avg)

2.72M (1.02M)

Day's Range

34.06-35.42

52Wk Range

30.80-55.99

Market Cap.

4.28B

Dividend Rate ( Yield )

-

Beta

1.42

Shares Outstanding

123.45M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 269.26M

    • Net Income

    • -62.52M

    • Market Cap.

    • 4.28B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -26.64

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.42

    • Forward P/E

    • -54.35

    • Price/Sales

    • 15.46

    • Price/Book Value

    • 18.94

    • Price/Cash flow

    • 476.19

      • EBITDA

      • -54.25M

      • Return on Capital %

      • -15.65

      • Return on Equity %

      • -31.64

      • Return on Assets %

      • -15.65

      • Book Value/Share

      • 1.83

      • Shares Outstanding

      • 123.45M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 47.33

        • Credit Rating

        • -

        • Analysts

        • 6

        • EPS Estimate

        • -0.68

        • Cashflow Estimate

        • -0.60

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -7.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 50.19

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 90.85

            • 82.75

            • Pre-Tax Margin

            • -26.64

            • 39.38

            • Net Profit Margin

            • -26.64

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -85.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.07

              • 2.92

              • Quick Ratio

              • 3.70

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 2.08

              • 2.21

              • Book Value/Share

              • 1.83

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -58.14

                • 188.68

                • P/E Ratio 5-Year High

                • -93.76

                • 634.30

                • P/E Ratio 5-Year Low

                • -13.83

                • 124.82

                • Price/Sales Ratio

                • 15.46

                • 8.72

                • Price/Book Value

                • 18.94

                • 7.95

                • Price/Cash Flow Ratio

                • 476.19

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -31.64

                    (-45.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -15.65

                    (-22.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -31.64

                    (-45.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 0.73

                  • 1.48

                  • Asset Turnover

                  • 0.59

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -62.86M
                  Operating Margin
                  -23.35
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  476.19
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  76.65%

                  Mutual Fund Ownership

                  51.47%

                  Float

                  56.37%

                  5% / Insider Ownership

                  1.34%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    8,620,443

                  • 0.38

                  • 6.98

                  • PrimeCap Odyssey Growth Fund

                  •  

                    4,656,400

                  • 0.00

                  • 3.78

                  • Columbia Acorn Fund

                  •  

                    4,001,000

                  • -9.97

                  • 3.24

                  • PrimeCap Odyssey Aggressive Growth Fund

                  •  

                    2,969,700

                  • -0.56

                  • 2.41

                  • Fidelity® Series Growth Company Fund

                  •  

                    2,079,042

                  • 0.38

                  • 1.68

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,983,060

                  • 0.00

                  • 1.61

                  • Vanguard Small Cap Index

                  •  

                    1,715,374

                  • -0.10

                  • 1.39

                  • Fidelity Advisor® Growth Opportunities

                  •  

                    1,665,767

                  • 0.00

                  • 1.35

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,610,287

                  • 0.15

                  • 1.30

                  • iShares Nasdaq Biotechnology

                  •  

                    1,600,122

                  • 0.24

                  • 1.21

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    22,472,229

                  • +8.36%

                  • 18.22

                  • Fidelity Management and Research Company

                  •  

                    18,460,516

                  • +0.14%

                  • 14.97

                  • Baillie Gifford & Co Limited.

                  •  

                    13,076,781

                  • +1.68%

                  • 10.60

                  • PRIMECAP Management Company

                  •  

                    10,895,800

                  • -1.01%

                  • 8.83

                  • Columbia Wanger Asset Management LLC

                  •  

                    6,610,000

                  • -0.24%

                  • 5.36

                  • Vanguard Group, Inc.

                  •  

                    6,219,143

                  • -1.61%

                  • 5.04

                  • BlackRock Advisors LLC

                  •  

                    6,093,332

                  • -30.71%

                  • 4.94

                  • Capital Guardian Trust Company

                  •  

                    5,175,692

                  • -15.86%

                  • 4.20

                  • Wasatch Advisors Inc.

                  •  

                    2,843,347

                  • +32.46%

                  • 2.31

                  • BlackRock Fund Advisors

                  •  

                    2,683,155

                  • -1.92%

                  • 2.18

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administ...moreration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attach...moreed by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.lessless

                  Key People

                  Dr. Clay B. Siegall,PhD

                  CEO/Chairman of the Board/Co-Founder/Director/President

                  Todd E. Simpson

                  CFO/Chief Accounting Officer

                  Dr. Vaughn B. Himes,PhD

                  Executive VP, Divisional

                  Christopher S. Boerner

                  Executive VP, Divisional

                  Jonathan G. Drachman

                  Chief Medical Officer/Executive VP, Divisional

                  • Seattle Genetics Inc

                  • 21823 - 30th Drive South East

                  • Bothell, WA 98021

                  • USA.Map

                  • Phone: +1 425 527-4000

                  • Fax: +1 425 527-4001

                  • seattlegenetics.com

                  Incorporated

                  1997

                  Employees

                  582

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: